Liyan Jiang

circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity

Botai Li, Lili Zhu, Chunlai Lu et al. · Nature Communications · 2021 · 860 citations · Full text

Medicine, Cancer Biology, Oncology +17

circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1

Zhuoan Cheng, Chengtao Yu, Shaohua Cui et al. · Nature Communications · 2019 · 528 citations · Full text

Medicine, Cancer Biology, Oncology +17

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

Ying Cheng, Liang Han, Lin Wu et al. · JAMA · 2022 · 456 citations · Full text

Medicine, Oncology, Pharmacology +17

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang, Caicun Zhou, Wenxiu Yao et al. · The Lancet Oncology · 2022 · 395 citations

Medicine, Oncology, Pharmacology +11

Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer

Liyan Jiang, Jiaqi Huang, Brandon W. Higgs et al. · PLoS Genetics · 2016 · 279 citations · Full text

Life Sciences, Genetics, Oncology +16